INSPIRE IVF Public Company LimitedSET: IVF🇹🇭 TH

MD&A · 2025

Overview of Operations

Overview of Operations

Revenue from sales and services

The Company’s service revenue for 2025 and 2024 amounted to THB 61.87 million and THB 105.70 million, respectively, representing a decrease of THB 43.83 million or 41.46%. The decline in service revenue in 2025 compared to 2024 was primarily attributable to a reduction in the use of regenerative medicine wellness services for infertility patients, including NAD+ and DFPP. These services are high-value offerings. In addition, the current unfavorable economic conditions led to a decrease in customer demand for such services, resulting in a significant decline in the Company’s revenue in 2025 compared to 2024.

Cost of sales and services

The Company’s cost of sales and services for 2025 and 2024 amounted to THB 42.92 million and THB 44.06 million, respectively, representing a decrease of THB 1.14 million or 2.60%. The Company’s cost of sales and services comprises: -Medicines and medical supplies; -Professional fees for physicians and medical technologists; -Salaries and employee expenses for medical staff, nurses, and medical technologists; -Diagnostic expenses, including blood tests and embryo genetic testing; -Depreciation, including depreciation of medical equipment and depreciation of right-of-use assets for building leases; and -Other costs, including utilities, and repair and maintenance of medical equipment. The decrease in cost of sales and services was primarily attributable to the decline in revenue from sales and services.

Gross profits and gross profit margins

The Company’s gross profit for 2025 and 2024 amounted to THB 18.96 million and THB 61.64 million, respectively, representing gross profit margins of 30.64% and 58.32%, respectively. The decrease in gross profit in 2025 compared to 2024 was primarily attributable to the decline in service revenue, while the Company incurred higher costs, particularly depreciation expenses and personnel compensation. As a result, gross profit decreased, with a gross profit margin of 30.64%.

Selling expenses

The Company’s selling expenses for 2025 and 2024 amounted to THB 15.52 million and THB 15.24 million, respectively, representing an increase of THB 0.28 million or 1.84%. The Company’s selling expenses for 2025 and 2024 were relatively similar in amount.

Administrative expenses

The Company’s administrative expenses for 2025 and 2024 amounted to THB 28.73 million and THB 20.19 million, respectively, representing an increase of THB 8.54 million or 42.31%. The increase in administrative expenses in 2025 compared to 2024 was primarily attributable to the recruitment of additional personnel, adjustments to employee compensation, and bonus payments, resulting in higher staff-related expenses. In addition, the Company incurred expenses related to overseas travel to meet with potential partners and due diligence costs for target businesses that the Company considered to have investment potential. Such actions are in line with the Company’s objectives for the utilization of IPO proceeds, namely overseas branch expansion and investment in high-potential businesses.

Financial costs

The Company’s finance costs for 2025 and 2024 amounted to THB 4.39 million and THB 4.67 million, respectively, representing a decrease of THB 0.28 million or 6.00%. The Company’s finance costs arose from the recognition of interest expenses on right-of-use assets for building leases.

Net profits

The Company’s net profit (loss) for 2025 and 2024 amounted to THB (17.37) million and THB 22.15 million, respectively, representing a decrease of THB 39.52 million or 178.43%. The decline in net profit was primarily attributable to a significant decrease in revenue from sales and services, while administrative expenses increased substantially. As a result, the Company reported a net loss of THB 17.37 million for 2025, representing a net profit margin of (24.86%).

Assets

The Company’s total assets as at the end of 2025 and 2024 amounted to THB 598.85 million and THB 635.69 million, respectively. These comprised current assets, including cash and cash equivalents, and non-current assets, including leasehold improvements and equipment, as well as right-of-use assets. The decrease in total assets as at the end of 2025 compared to 2024 was primarily attributable to a reduction in cash and cash equivalents resulting from dividend payments based on the 2024 operating results, cash payments for deposits related to share acquisitions for investment in high-potential businesses, and the operating loss incurred in 2025.

Liabilities

The Company’s total liabilities as at the end of 2025 and 2024 amounted to THB 70.52 million and THB 78.11 million, respectively. These comprised current liabilities, including trade payables and other current payables, as well as lease liabilities. The decrease in total liabilities as at the end of 2025 compared to 2024 was primarily attributable to repayments made to trade payables and other current payables, as well as the settlement of lease liabilities in accordance with the scheduled installment payments.

Shareholders' equity

The Company’s total shareholders’ equity as at the end of 2025 and 2024 amounted to THB 528.34 million and THB 557.58 million, respectively. This comprised issued and paid-up share capital, share premium, and retained earnings. The decrease in shareholders’ equity as at the end of 2025 compared to 2024 was primarily attributable to dividend payments from the net profit for 2024 and the net loss incurred for 2025.

Debt Securities with Financial Ratio Requirements

Debt Securities with Financial Ratio Requirements Issued?

No

Factors That May Affect Financial Condition

Factors or Incidents That May Materially Affect Financial Condition

Internal Factors

1. Company Restructuring

The company has developed a plan to restructure in order to lay a long-term foundation that will enable it to conduct business, strengthen, and enhance its competitiveness in the rapidly changing economic environment. This includes business diversification to reduce dependency on any single business and to ensure sustainable growth in the long term, as well as to maximize benefits for the company and its shareholders.

2. Expansion of Branches Domestically and Internationally

The Company plans to establish a branch in the United Arab Emirates to expand its foreign customer base, particularly targeting high-purchasing-power customers in the Middle East region. The planned branch will operate as a Sales Representative Office, which will be responsible for marketing activities, customer acquisition, and serving as a coordination center with the Company, as well as referring customers to receive treatment in Thailand.

In addition, the Company has been pursuing collaboration with partners that are hospitals or healthcare operators who recognize the Company’s reputation and potential and are interested in expanding their businesses to jointly provide infertility treatment services with the Company.

3. Investment in Potential Businesses

The Company plans to invest or co-invest in related businesses or innovative ventures that support the Company’s operations, such as wellness services. Currently, the Company is in the final stage of conducting Due Diligence. The information will subsequently be presented to the Board of Directors for consideration and approval, and will be disclosed in accordance with the regulations of the Stock Exchange of Thailand.

External Factors

1. Changes in Laws, Regulations, and Rules Related to the Business The company is obligated to comply with various laws related to its business operations. In the event of changes in laws, regulations, or rules affecting the business, such as laws on surrogacy, these changes could have a significant impact on the company's financial position or operations, both positively and negatively.

2. Industry Competition Competition in the fertility treatment sector is expected to increase, as businesses in the same field plan to continuously expand their branches. Additionally, the number of professionals in the fertility treatment field is increasing, both through education and staff development in various institutions. Therefore, there is a possibility of new establishments opening to support the growing medical tourism in Thailand, which is promoted by the government.

Contents